The ongoing phase III RC48-C007 (NCT04714190) trial will further compare the effectiveness of Disitamab vedotin with a standard treatment strategy as a second-line treatment and beyond in patients with advanced HER2-positive GC. Here, ERBB2 is linked to gastric cancer.